International Centre for Diarrhoeal Disease Research, Bangladesh

20 marketed · 7 in Phase 3

Quick facts

Marketed products

Phase 3 pipeline

Phase 2 pipeline

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about International Centre for Diarrhoeal Disease Research, Bangladesh

What are International Centre for Diarrhoeal Disease Research, Bangladesh's marketed drugs?

Top marketed products include Bivalent OPV 2 week interval, Bivalent OPV 4 week interval, Fractional IPV( fIPV), Hepa-B, Hexavalent vaccine, Hypo-osmolar ORS.

What is International Centre for Diarrhoeal Disease Research, Bangladesh's pipeline?

International Centre for Diarrhoeal Disease Research, Bangladesh has 7 drugs in Phase 3, 1 in Phase 2, 1 in Phase 1. Late-stage candidates include Amylase resistant starch added ORS, Blood and adrenaline, Blood and Dopamine, Measles and Rubella (MR).

Related